Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study
British Journal of Surgery · 2025
DOI: 10.1093/bjs/znaf281 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Surgery, 2025. Verfasst von Carmen Rubio-Alarcón und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colonic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health∼Holland, Commonwealth Foundation, US National Institutes of Health.
Abstract (Originalsprache)
Background
Circulating tumour DNA (ctDNA) is a promising biomarker to guide clinical decision-making. The aim of this study was to investigate the prognostic value of postoperative ctDNA in patients with stage III colon cancer who received adjuvant chemotherapy (ACT).
Methods
PROVENC3 was a multicentre prospective study of patients who underwent resection of pathological stage III colon cancer. Blood samples were collected at a median of 13 (interquartile range 4–20) days after resection. The presence of minimal residual disease was determined using Labcorp® Plasma Detect™, a novel tumour-informed whole genome sequencing (WGS) ctDNA test. The primary endpoint was 3-year time to recurrence (TTR). ctDNA status was further combined with pathological risk status to investigate the combined prognostic value.
Results
The median follow-up of the 209 patients who were included was 40 months. In total, 28 patients (13%) had detectable ctDNA after surgery. Postoperative ctDNA-positive patients had a worse TTR compared with ctDNA-negative patients (HR 6.2 (95% c.i. 3.4 to 11.2); P < 0.001). Of all ctDNA-positive patients, 36% did not develop recurrences during 3-year follow-up. Detectable ctDNA after ACT was associated with worse TTR (HR 7.9 (95% c.i. 3.9 to 15.9); P < 0.001). ctDNA status combined with pathological risk classification resulted in a 3-year recurrence risk that varied from 82% for pathological high-risk (pT4/N2) ctDNA-positive patients to 7% for pathological low-risk (pT1–3 N1) ctDNA-negative patients (HR 28.5 (95% c.i. 10.5 to 77.2); P < 0.001).
Conclusion
Postoperative ctDNA detection using a tumour-informed WGS test improves prognosis stratification in stage III colon cancer and may help to personalize adjuvant treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Labcorp, Baltimore, Maryland, USA.
- Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
- Department of Epidemiology and Data Science, Amsterdam University Medical Centres, Location VU Medical Centre, Amsterdam, The Netherlands.
- Department of Laboratory Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Core Facility Molecular Pathology and Biobanking (CFMPB), The Netherlands Cancer Institute, Amsterdam, The Netherlands.
ORCID-Profile: Ingrid A Franken, Daan van den Broek, Miriam Koopman, Jeanine M L Roodhart, Remond J A Fijneman
Förderung
- Health∼Holland
- Commonwealth Foundation
- US National Institutes of Health
- Sacha Swarttouw-Hijmans Foundation
- Dutch Cancer Society
- NCI NIH HHS
- Netherlands Cancer Institute
- American Association for Cancer Research
Zitieren
APA
Rubio-Alarcón, C., Georgiadis, A., Franken, I. A., Wang, H., van Nassau, S. C. M. W., Schraa, S. J., van der Kruijssen, D. E. W., van Rooijen, K., Linders, T. C., Delis-van Diemen, P., Alkemade, M., Bolijn, A., Tijssen, M., Lemmens, M., Meiqari, L., Ketelaars, S. L. C., Closa-Mosquera, A., van Dongen, M. M. W., Lanfermeijer, M., …, & Other Members of the PLCRC-MEDOCC Group (2025). Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study. British Journal of Surgery. https://doi.org/10.1093/bjs/znaf281
Vancouver
Rubio-Alarcón C, Georgiadis A, Franken IA, Wang H, van Nassau SCMW, Schraa SJ, et al. Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study. British Journal of Surgery. 2025. doi:10.1093/bjs/znaf281
BibTeX
@article{RubioAlarcn2025,
author = {Rubio-Alarcón, Carmen and Georgiadis, Andrew and Franken, Ingrid A and Wang, Haoyue and van Nassau, Sietske C M W and Schraa, Suzanna J and van der Kruijssen, Dave E W and van Rooijen, Karlijn and Linders, Theodora C and Delis-van Diemen, Pien and Alkemade, Maartje and Bolijn, Anne and Tijssen, Marianne and Lemmens, Margriet and Meiqari, Lana and Ketelaars, Steven L C and Closa-Mosquera, Adria and van Dongen, Miranda M W and Lanfermeijer, Mirthe and Lissenberg-Witte, Birgit I and Bosch, Linda J W and Bisschop-Snetselaar, Teunise and Adriaans, Bregje C and Greer, Amy and Riley, David and White, James R and Greco, Christopher and Cox, Liam and Fox, Jesse and Victor, Kaitlin and Leech, Catherine and Angiuoli, Samuel V and Kok, Niels F M and Punt, Cornelis J A and van den Broek, Daan and Koopman, Miriam and Meijer, Gerrit A and Velculescu, Victor E and Roodhart, Jeanine M L and Coupé, Veerle M H and Sausen, Mark and Vink, Geraldine R and Fijneman, Remond J A and Other Members of the PLCRC-MEDOCC Group, Other Members of the PLCRC-MEDOCC Group},
title = {Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study},
journal = {British Journal of Surgery},
year = {2025},
doi = {10.1093/bjs/znaf281}
}
EUVIMED